Overview

Evaluation of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder

Status:
Completed
Trial end date:
2020-10-10
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of SPN-812, an extended-release formulation of viloxazine, in adults.
Phase:
Phase 3
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.